All News
Two Week Twitter (6.17.2022)
Dr. Jack Cush does a 2-week review of RheumNow Tweets on news and journal citations worth noting, along with some opinions on Telehealth, manpower, monkeypox and the price of drugs.
Read Article
PsA UPLIFT survey: do rheumatologists and patients agree on treatment goals?
POS0309 at EULAR 2022 highlighted both similarities and differences between our patients and ourselves when it comes to PsA disease and treatment strategies.
Read Article
Not All RA Drug Classes Are Created Equal
d
MedPage Today
Clear differences were apparent among the three major types of targeted medications for rheumatoid arthritis (RA) in a large European registry study.
Read Article
JAK/STAT pathway in pyoderma gangrenosum: a new therapeutic highway?
Pyoderma gangrenosum (PG) is rare, but often associated with different forms of arthritis, in particular rheumatoid arthritis and inflammatory bowel diseases.
Read Article
We've got a new download available titled "Travel Tips for Arthritis Travelers"
Head over to RheumNow and download today.
https://t.co/COamlQvlIs https://t.co/wxGBTtuv2f
Links:
Dr. John Cush RheumNow ( View Tweet)
JAKi not yet safe in pregnancy - theyre fetotoxic at high doses (animals). JAKi do cross placenta. ACR Guidelines: no position due to no data. 47 tofa Rheum & 15 UC maternal exposures - no signif probs. Paternal use of JAKi is ok.
https://t.co/PoIheshd2n https://t.co/gjTN2Uz4IP https://t.co/OAfLRvSFBs
Dr. John Cush RheumNow ( View Tweet)
#EULAR2022 has concluded but you can find all our coverage here https://t.co/s62OVJPQ86 https://t.co/QAvPQYCABj
Links:
Dr. John Cush RheumNow ( View Tweet)
From OP Internationa: The Clinician’s Guide to prevention & Rx of OP -concise recommendations regarding prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women & men >50 yrs of age https://t.co/z3ZJ3lIplG
Links:
Dr. John Cush RheumNow ( View Tweet)
Learn more about the IL-23 pathway and our clinical research in #psoriaticdisease here: https://t.co/jDuYR9fZ10 Sponsored by Janssen @JanssenUS@JanssenUS https://t.co/kjekl1teNX
Links:
Dr. John Cush RheumNow ( View Tweet)
JAK/STAT pathway in pyoderma gangrenosum: a new therapeutic highway?
Pyoderma gangrenosum (PG) is rare, but often associated with different forms of arthritis, in particular rheumatoid arthritis and inflammatory bowel diseases.
https://t.co/QHNHsyWNbx https://t.co/Arlq03uiLE
Links:
Dr. John Cush RheumNow ( View Tweet)
Flares Not Increased Following RZV Injections
Insurance claims analysis has shown that the use of the RZV for prevention of HZ was highly used in patients with IMIDs and was safe, as higher rates of arthritis flares were not evident.
https://t.co/E27oIBlEDb https://t.co/VbtDnmRYzO
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: Dr. Lucy Carter on RNA-Seq analysis to determine who's at risk for SLE
Dr. Yusof interviews Dr. Lucy Carter ( @LucyCarter6), winner of the #EULAR2022 Best Abstract Award for her work on ANA positivity in those at-risk for progression to #SLE.
https://t.co/BdPnZRgwX4 https://t.co/g8xWWFthVC
Links:
Dr. John Cush RheumNow ( View Tweet)
COVID-19 hospitalization among Medicare diabled was ~50% higher (3,148/100k) than age matched pop. , and hospitalization rates increased with age in both groups. Among the disabled, American Indian or Alaska Natives had highest rate https://t.co/Xa4NlalHdf https://t.co/dP0c3ajQAW
Links:
Dr. John Cush RheumNow ( View Tweet)
Although Rheumatology currently ranks 2nd or 3rd in specialty use of telemedicine - the vast majority of rheums have given up on telehealth (<15%) https://t.co/iDNesBkOnN
Dr. John Cush RheumNow ( View Tweet)
Australian Bureau of Statistics 2017–2018 shows relative risk of undergoing knee replacement for OA increased with increasing BMI (Class 1- 3 obese females 55–64 yrs had 4.7 to 17.3 fold risk of KR. Same for obese Males (OR 3.4 - 5.8) more KR https://t.co/vcPmRgbzUH https://t.co/FrfTC9LNnR
Links:
Dr. John Cush RheumNow ( View Tweet)
31 systemic JIA pts: w/ systemic sxs (n=8), chronic arthritis (7), remission on meds (10) & remission off meds (6). High IL-18 levels & impaired IL-18 signaling in NK cells correlated with systemic Dz activity. High IL-18 impairs NK phosphorylation https://t.co/HlaQid7xGq https://t.co/0PbxC0pZtk
Links:
Dr. John Cush RheumNow ( View Tweet)
Lit search on (Lyme) Borrelia burgdorferi sensu lato shows global Bb seroprevalence =14.5% (top 3: Central Europe 20.7%,Eastern Asia 15.9%, Western Europe 13.5%). Bb seropositivity assoc w/ ≥50 yrs, men & residence of rural area https://t.co/fvr845s5CC https://t.co/TLNumNuXnH
Links:
Dr. John Cush RheumNow ( View Tweet)
Balance and falls studied in 228 #RA pts (24-85 yrs) followed x 1yr; 20% had at least one fall; risks included Age (OR 1.04), HAQ (OR 1.62), low FICSIT-4 score (OR 2.38) & 1-leg standing (OR 2.14). 1-leg stand is a good screening tool https://t.co/u9v8unC0gA https://t.co/oD0sgFxiQm
Links:
Dr. John Cush RheumNow ( View Tweet)
Small study 34 biologic-naive RA pts starting abatacept. Remission achieved 47.1% of early and 23.5% established RA. Remission @ 6 mos predicted by Baseline LOWER IL-6 levels ≤ 8.4 pg/ml, (66.7%) and CD4+CD25+FoxP3+ cells ≥ 6% (83.3%) https://t.co/N93E9M4M15
Links:
Dr. John Cush RheumNow ( View Tweet)
There are 494K PCPs in the USA, While up to 1/3 will "refill" DMARDs, only 6-9% are confident or knowledgeable in "initiating" DMARD therapy in #RA. GIGANTIC NEED FOR PCP education in MSK & Rheum Dz https://t.co/VjgWWDt3nX https://t.co/dTRXxsrzG5
Dr. John Cush RheumNow ( View Tweet)